On March 11, 2025 Luminary Therapeutics reported that it has been awarded up to $5.8 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to develop a mesothelin chimeric antigen receptor T cells ("CAR T") targeting non-small cell lung cancer and colorectal cancer (Press release, Luminary Therapeutics, MAR 11, 2025, View Source [SID1234651084]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"While CAR T therapies have been effective for blood cancers, solid tumors like lung and colorectal cancers have proven to be resistant to current CAR T therapies", said Jeff Liter, CEO and President of Luminary Therapeutics. "This project combines an allogeneic CAR T for direct killing of tumor cells with the ability to utilize the patient’s immune system to target tumor cells by also leveraging the gamma delta cell’s ability to work as professional antigen-presenting cells (APCs) and presenting tumor-specific neo antigens. Combining neo antigen-presenting functions with CAR directed killing in a single cellular chassis will increase the effectiveness of cellular therapies by recruiting a patient’s immune system to increase the response and durability of tumor clearance."
Since its founding in 2019, Luminary Therapeutics has developed a proprietary gamma delta expansion platform that is unique in the industry and allows Luminary to manufacture cell therapies with a significantly lower cost and reduced time to clinic. Leveraging this platform, the Company has developed two groundbreaking therapeutic programs designed to overcome current challenges of CAR T therapies for solid tumors and autoimmune disorders. The award from ARPA-H represents not only a significant step forward in scaling Luminary’s therapeutic pipeline, while expanding the capabilities of its gamma delta expansion platform, but also aligns with ARPA-H’s mission to improve health outcomes for everyone.